Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
17.03
0.00 (0.00%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Theravance Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
53.81105.9-56.42-55.19872.13-199.43
Depreciation & Amortization
5.795.646.126.157.028.6
Loss (Gain) From Sale of Assets
-0.040.031.35-2.720.04
Asset Writedown & Restructuring Costs
--4.51---
Loss (Gain) From Sale of Investments
-3.62-2.83-2.51-1.9--
Stock-Based Compensation
19.5518.4821.3925.3739.7362.06
Other Operating Activities
-0.99-9.15-5.035.56-960.95-67.5
Change in Accounts Receivable
1.54-27.1-0.97-0.69-2.721.8
Change in Accounts Payable
-1.020.330.750.01-1.61-3.53
Change in Unearned Revenue
----0.22-0.19-11.46
Change in Income Taxes
-15.4510.489.911.163.95-0.19
Change in Other Net Operating Assets
-5.87136.7610.67-8.54-17.08-26.17
Operating Cash Flow
53.74238.54-11.54-27-186.99-207.86
Operating Cash Flow Growth
-78.07%-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.01-0.04-0.33-2.49-0.57-3.41
Sale of Property, Plant & Equipment
---1.514.580.01
Investment in Securities
-107.46-105.2414.91-31.7254.87127.89
Other Investing Activities
---2.29-1,095-
Investing Cash Flow
-107.47-105.2812.28-32.71,154124.49

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
-----631.6-10.73
Net Debt Issued (Repaid)
-----631.6-10.73
Issuance of Common Stock
2.140.790.610.620.8111.65
Repurchase of Common Stock
-10.58-4.03-3.1-199.55-132.28-9.06
Other Financing Activities
----4.28-
Financing Cash Flow
-8.44-3.25-2.5-198.93-758.8191.86

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-62.16130.01-1.75-258.63208.218.5

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
53.73238.5-11.87-29.49-187.56-211.26
Free Cash Flow Growth
-78.05%-----
Free Cash Flow Margin
51.51%221.93%-18.43%-51.35%-365.29%-381.96%
Free Cash Flow Per Share
1.034.63-0.24-0.53-2.55-3.04
Levered Free Cash Flow
5.3-4.12-42-12.2224-115.85
Unlevered Free Cash Flow
6.02-2.58-40.41-10.7527.98-110.5

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
----22.2439.03
Cash Income Tax Paid
24.5527.880.110.02117.97-4.09
Change in Working Capital
-20.8120.4720.36-8.3442.35-39.55
SEC Filings: 10-K · 10-Q